Blog Archives

Pembrolizumab (Keytruda): Clinical trials on hold

September 2, 2017 – The American Food & Drug Administration (FDA) has announced that two clinical trials with Pembrolizumab (Keytruda) in patients with multiple myeloma have been put on hold. The FDA informs the public, health care professionals, and oncology clinical investigators about the risks associated with the use of Pembrolizumab (Keytruda) in combination with dexamethasone and an immunomodulatory agent (Lenalidomide (Revlimid) or Pomalidomide (Pomalyst)) for the treatment of patients with multiple myeloma.

Read more ›

Tags: , , , , , , , , , , ,

Orlistat: Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers

August 30, 2016 – The present article which just appeared in August 2016 issue of  PLOS Medicine illustrates how the inaccurate and biased to say the least the assessment and the reporting of adverse drug reactions by pharmaceutical companies throughout study protocols, investigators brochures,

Read more ›

Tags: , , , , , ,

Immunemodulation: Cancer drug trial halted after three test subjects die

July 12, 2016 – The American Food & Drug Administration (FDA) has notified Juno Therapeutics Inc. that a clinical hold has been placed on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL), known as the “ROCKET” trial.

Read more ›

Tags: , , , , , , ,

The betrayed educated patient: A significant percentage of completed clinical trials on drugs are never published

May 01, 2016 – The present post addresses a very disturbing issue in connection with clinical trials and the disclosure of the results in public. The cited study throws a dubios light on the readiness of sponsors to inform patients, i.e. their future end user clients, on the outcome of clinical trials and to openly divulge pros and cons of their products.

Read more ›

Tags: , , , , ,

Under scrutiny: The EMA reviews cancer medicine Idelalisib (Zydelig) after the occurrence of serious adverse effects, some of them fatal, in three clinical trials

 March 20, 2016 – The European Medicines Agency (EMA) has, at the request of the European Commission, has started a review of the cancer medicine Idelalisib (Zydelig), which is authorised in the European Union to treat two types of rare blood cancers called chronic lymphocytic leukaemia (CLL) and follicular lymphoma (FL) (one of a group of cancers called Non-Hodgkin lymphoma).

Read more ›

Tags: , , , , , , , ,

New Treatment Modality: Nivolumab (Opdivo) has been approved for the treatment of patients with previously treated metastatic squamous non-small cell lung cancer (NSCLC)

June 17, 2015 – Bristol Myers Squipp recently announced that the U.S. Food and Drug Administration (FDA) has approved Nivolumab (Opdivo) injection, for intravenous use, for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. 

Read more ›

Tags: , , , , , ,

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Researchers develop new approach to study the genetics of human disease July 7, 2020
    Many heritable immune diseases such as rheumatoid arthritis and blood-cell related traits derive from critical proteins not being made or not functioning correctly. But exactly how a person's genes, the regulation of these genes and how the resulting proteins interact to cause disease is not widely understood.
  • Common inherited genetic variant identified as frequent cause of deafness in adults July 6, 2020
    A common inherited genetic variant is a frequent cause of deafness in adults, meaning that many thousands of people are potentially at risk, reveals research published online in the Journal of Medical Genetics.
  • Rsearchers create an analytic tool that opens a new frontier of cancer discovery July 6, 2020
    Gene coding regions constitute 2% of the human genome. St. Jude Children's Research Hospital scientists have developed a computational tool to identify alterations that drive tumor formation in the remaining 98% of the genome. The method will aid discovery of oncogenes and advances in precision medicine for children and adults with cancer.
  • Discovery of new disease-susceptibility gene for steroid-sensitive nephrotic syndrome July 3, 2020
    An international research collaboration, including Professor Iijima Kazumoto et al. (of the Department of Pediatrics, Kobe University Graduate School of Medicine) has revealed that NPHS1 is a disease-susceptibility gene for steroid-sensitive nephrotic syndrome in children. The NPHS1 gene encodes nephrin, a component protein for the renal glomerulus slit diaphragm, which prevents protein from being passed […]
  • How digital tools can advance quality and equity in genomic medicine July 3, 2020
    The pandemic has forced health care providers to find new ways to connect with patients through screens. For genetic specialists, who provide patients and families with genetic testing for conditions linked to DNA, connecting with patients is an important part of helping them make informed medical decisions.
  • A novel therapeutic target for recovery after stroke July 7, 2020
    IBS researchers have discovered a new mechanism to explain the effects of subcortical strokes and a new possible therapeutic approach.
  • Scientists create new device to light up the way for quantum technologies July 7, 2020
    Researchers at CRANN and the School of Physics at Trinity College Dublin, Ireland, have created an innovative new device that will emit single particles of light, or photons, from quantum dots that are the key to practical quantum computers, quantum communications, and other quantum devices.
  • Long-acting injectable form of HIV prevention outperforms daily pill in NIH study July 7, 2020
    A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than daily oral Truvada at preventing HIV acquisition among cisgender men who have sex with men and transgender women who have sex with men in a clinical trial sponsored by NIH. Findings […]
  • Portable system boosts laser precision, at room temperature July 7, 2020
    Physicists at MIT have designed a quantum "light squeezer" that reduces quantum noise in an incoming laser beam by 15 percent. It is the first system of its kind to work at room temperature, making it amenable to a compact, portable setup that may be added to high-precision experiments to improve laser measurements where quantum […]
  • Fighting E. coli with E. coli July 7, 2020
    According to findings published this week in mBio, Nissle, a strain of Escherichia coli, is harmless to intestinal tissue and may protect the gut from enterohemorrhagic E. coli, a pathogen that produces Shiga toxin.
Top